<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02446093</url>
  </required_header>
  <id_info>
    <org_study_id>PaTK02</org_study_id>
    <nct_id>NCT02446093</nct_id>
  </id_info>
  <brief_title>Neoadjuvant GMCI Plus mFOLFIRINOX and Chemoradiation for Non-Metastatic Pancreatic Adenocarcinoma</brief_title>
  <acronym>PaTK02</acronym>
  <official_title>Neoadjuvant GMCI Plus Modified FOLFIRINOX and Chemoradiation for Advanced Non-Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advantagene, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Advantagene, Inc.</source>
  <brief_summary>
    <textblock>
      The study will investigate if the addition of GMCI to neoadjuvant mFOLFIRINOX +
      chemoradiation is safe and improves the clinical outcome of borderline resectable and
      unresectable locally advanced pancreatic adenocarcinoma, as measured by resection rate,
      progression-free survival and overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current protocol is designed to delivery multiple courses of GMCI timed with a series of
      neoadjuvant debulking therapies- modified FOLFIRINOX (mFX) chemotherapy followed by
      gemcitabine-radiation (GR) followed by surgery- to capitalize on the synergies with the
      different treatment modalities.

      This protocol includes two phases: Phase 1b followed by Phase 2. The Phase 1b evaluates the
      safety and feasibility of mFX+GR+surgery in combination with GMCI. Patients will be enrolled
      on the Phase 1b based on the definition of dose limiting toxicity (DLT), waiting periods and
      stopping rules described in the protocol. The Phase 2 is a randomized study comparing a test
      group receiving GMCI added to mFX+GR+surgery to a control arm receiving mFX+GR followed by
      surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resection rate</measure>
    <time_frame>4 months</time_frame>
    <description>The percentage of patients receiving an R0 resection will be compared between the two arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety graded by CTC ver4.0</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency of adverse events will be compared between the two arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of patients alive at 2 years will be compared between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>The PFS curves will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Test Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GMCI + mFOLFIRINOX + Gemcitabine + Radiation + Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mFOLFIRINOX + Gemcitabine + Radiation + Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GMCI</intervention_name>
    <description>Intratumoral cytotoxic immunotherapy using an adenoviral vector expressing HSV-tk followed by anti-herpetic prodrug valacyclovir</description>
    <arm_group_label>Test Arm</arm_group_label>
    <other_name>AdV-tk (aglatimagene besadenovec) + valacyclovir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFIRINOX</intervention_name>
    <description>fluorouracil, irinotecan and oxaliplatin</description>
    <arm_group_label>Test Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Modified FOLFIRINOX (mFX)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine chemotherapy given with radiation</description>
    <arm_group_label>Test Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <arm_group_label>Test Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Radiation given with gemcitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Pancreaticoduodenectomy (Whipple)</description>
    <arm_group_label>Test Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Pancreatic cancer resection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathological diagnosis of pancreatic adenocarcinoma before first treatment but may be
             enrolled with presumed diagnosis based on clinical and radiologic evaluation with
             confirmation made by biopsy at time of EUS prior to AdV-tk injection

          -  Patients must be deemed to be in adequate health to undergo major surgery
             (pancreaticoduodenectomy)

          -  Tumor accessible for injection that is classified as borderline-resectable or locally
             advanced but considered potentially resectable after central review by surgical
             investigators. Resection may include major vascular resection with reconstruction as
             needed.

          -  Age 18-76 years

          -  Performance status ECOG 0-1

          -  SGOT (AST)&lt;3x upper limit of normal

          -  Total bilirubin ≤2mg/dl

          -  Creatinine&lt;2mg/dl

          -  Calculated creatinine clearance &gt;30ml/m

          -  WBC&gt;3000/mm3

          -  Absolute neutrophil count (ANC)&gt;1500/mm3

          -  Platelets&gt;100,000/mm3

          -  Hemoglobin &gt; 9 g/dL.

          -  Patients must give study specific informed consent prior to enrollment

        Exclusion Criteria:

          -  Baseline peripheral sensory neuropathy ≥ grade 2

          -  Primary hepatic dysfunction including known cirrhosis or active hepatitis. Patients
             with biliary obstruction must be stented prior to initiating treatment.

          -  Evidence of clinically significant pancreatitis as determined by the investigator

          -  Evidence of significant ascites as determined by the investigator

          -  Patients on systemic corticosteroids (&gt;10 mg prednisone per day or equivalent) or
             other systemic immunosuppressive drugs

          -  Known to be HIV+

          -  Pregnant or breast-feeding. Female patients of childbearing age must have negative
             serum or urine pregnancy test within 1 week of beginning therapy.

          -  Other current malignancy (except squamous or basal cell skin cancers)

          -  Prior abdominal radiation therapy or prior chemotherapy for pancreatic cancer

          -  Other serious co-morbid illness or compromised organ function

          -  Known sensitivity or allergic reactions to acyclovir or valacyclovir
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cape Coral Hospital</name>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <zip>33990</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Piacente</last_name>
      <phone>239-430-3263</phone>
      <email>Rachel.Piacente@21co.com</email>
    </contact>
    <investigator>
      <last_name>Brian Rajca, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lee Memorial Hospital</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel E Piacente</last_name>
      <phone>239-430-3263</phone>
      <email>Rachel.Piacente@21co.com</email>
    </contact>
    <investigator>
      <last_name>Mark Bloomston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33966</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel E Piacente</last_name>
      <phone>239-430-3263</phone>
      <email>Rachel.Piacente@21co.com</email>
    </contact>
    <investigator>
      <last_name>Mark Bloomston, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamida Umar</last_name>
      <phone>614-685-6406</phone>
      <email>Hamida.Umar@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Mary Dilhoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Uscanga, M.D</last_name>
      <phone>+52 (55)54870900</phone>
      <phone_ext>4401</phone_ext>
      <email>luis.uscangad@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreas</keyword>
  <keyword>pancreatic adenocarcinoma</keyword>
  <keyword>GMCI</keyword>
  <keyword>AdV-tk</keyword>
  <keyword>aglatimagene besadenovec</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

